Nascent Biotech Inc. (NBIO)
OTCQB OTCQB Primary Summary
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, is pleased to provide an overview of the Company's presentation at The Emerging Growth Conference on July 18, 2024. Click here to view the Company's entire presentation.
Nascent Biotech Inc. (NBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nascent Biotech Inc. ever had a stock split?
Nascent Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sean Carrick CEO | OTCQB Exchange | 63108Q101 CUSIP |
| US Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company engaged in the development of monoclonal antibodies aimed at treating various forms of cancer. Operating from North Palm Beach, Florida, the company is at the forefront of developing innovative cancer therapies. Its flagship product, Pritumumab, targets brain cancer malignancies such as glioblastoma and malignant astrocytoma, alongside epithelial cancers like lung, breast, colon, brain, and pancreas cancer. Nascent Biotech is also in the process of developing a proprietary technology platform named MultiPharm, which holds promise for cancer therapy and potentially for diseases such as diabetes, autoimmunity, and for use in transplantation.
Products and Services
-
Pritumumab:
This novel monoclonal antibody is at the core of Nascent Biotech's product portfolio, designed to treat patients with various brain cancer malignancies, including glioblastoma and malignant astrocytoma. It also shows potential in treating epithelial cancers such as lung, breast, colon, brain, and pancreas cancers. The innovative approach of Pritumumab represents a significant leap forward in the management of these hard-to-treat cancers.
-
MultiPharm Technology Platform:
A proprietary technology platform under development by Nascent Biotech, MultiPharm, promises to revolutionize cancer therapy. The platform is being tailored not only for cancer treatment but also for managing other serious conditions such as diabetes, autoimmunity, and in the field of transplantation, highlighting the company's commitment to diversifying and amplifying its impact on healthcare.
-
CLNH5:
Another innovative project that Nascent Biotech, Inc. is currently developing. Although specific details about CLNH5's application and potential are sparse, its inclusion in the company's pipeline suggests a broader strategic move towards expanding its array of therapeutic offerings.
-
Collaboration with Hypospray Pharma:
Nascent Biotech is collaborating with Hypospray Pharma to develop an alternative delivery mechanism for Pritumumab. This partnership underscores the company's dedication to improving patient outcomes and accessibility of its therapies, demonstrating an innovative approach to drug delivery systems that cater to the needs of patients who could benefit from Pritumumab.
